Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine tablets add-on to Rebif in active multiple sclerosis
2006-003366-33Phase 2Terminated
- Sponsor
- Merck Serono
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cladribine in multiple sclerosis (MS) (3 arms), sponsored by Merck Serono. Primary endpoint: Safety and tolerability. Started Jan 2008; status: terminated.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-003366-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003366-33.